Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11388923 | 0.99 | ADORA2B (0.61) | ADORA2BADORA2ATSHRLMNAHTT | |
| SCHEMBL8318291 | 0.94 | ADORA2B (0.58) | ADORA2BADORA2ATSHRLMNAHTT | |
| SCHEMBL683888 | 0.91 | SMN1; SMN2 (0.51) | ADORA2BADORA2ATSHRLMNANPSR1 | |
| Hydrochloric Acid SCHEMBL11381649 | 0.89 | SMN1; SMN2 (0.50) | ADORA2BADORA2ATSHRLMNANPSR1 | |
| SCHEMBL684271 | 0.88 | TSHR (0.54) | ADORA2BADORA2ATSHRLMNAHTT | |
| Hydrochloric Acid SCHEMBL11384998 | 0.87 | TSHR (0.53) | ADORA2BADORA2ATSHRLMNAHTT | |
| SCHEMBL683542 | 0.86 | NCOA3 (0.54) | ADORA2BADORA2ATSHRLMNAHTT | |
| SCHEMBL7030152 | 0.86 | ADORA2B (0.70) | ADORA2BADORA2ATSHRLMNAHTT | |
| SCHEMBL682765 | 0.85 | MAOB (0.49) | ADORA2BADORA2AMAOBALDH1A1 | |
| Hydrochloric Acid SCHEMBL11381068 | 0.85 | NCOA3 (0.53) | ADORA2BADORA2ATSHRLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4299832-A | Substituted theophylline compounds | FISONS LIMITED (GB) | 1981-11-10 | — | — | US | claimed |
| EP-0011399-A1 | N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them | FISONS plc (GB) | 1980-05-28 | — | — | EP | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ADORA2B 786/4885ADORA2A 898/4885TSHR 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.